Printed on recycled paper
132nd MAINE LEGISLATURE
FIRST REGULAR SESSION-2025
Legislative Document No. 582S.P. 265 In Senate, February 25, 2025
An Act to Require Health Insurance Carriers to Provide Coverage
for Blood Testing for Perfluoroalkyl and Polyfluoroalkyl Substances
Received by the Secretary of the Senate on February 19, 2025. Referred to the Committee
on Health Coverage, Insurance and Financial Services pursuant to Joint Rule 308.2 and ordered
printed.
DAREK M. GRANT
Secretary of the Senate
Presented by Senator BRENNER of Cumberland.
Cosponsored by Representative FLYNN of Albion and
Senators: BAILEY of York, BALDACCI of Penobscot, BLACK of Franklin, INGWERSEN of
York, Representatives: ARFORD of Brunswick, HYMES of Waldo, MATHIESON of Kittery,
PARRY of Arundel. Page 1 - 132LR0980(01)
1
2 is enacted to read:
3
4 As used in this section, unless the context otherwise indicates,
5 "perfluoroalkyl and polyfluoroalkyl substances" or "PFAS" means any member of the class
6 of fluorinated organic chemicals containing at least one fully fluorinated carbon atom.
7 A carrier offering a health plan in this State shall provide
8 coverage for blood testing for perfluoroalkyl and polyfluoroalkyl substances that is
9 recommended by a provider as medically necessary health care for an enrollee. For the
10 purposes of this subsection, blood testing for PFAS is presumed to be medically necessary
11 health care for an enrollee if a provider determines that the enrollee meets clinical
12 guidelines for blood testing for PFAS established by the National Academies of Sciences,
13 Engineering, and Medicine, its successor organization or a comparable organization.
14 A health plan may not impose any deductible,
15 copayment, coinsurance or other cost-sharing requirement for the costs of blood testing
16 required to be covered under subsection 2. This subsection does not apply to a health plan
17 offered for use with a health savings account unless the federal Internal Revenue Service
18 determines that the requirements in this subsection are permissible in a high deductible
19 health plan as defined in the federal Internal Revenue Code, Section 223(c)(2).
20
21 The Legislature finds that the requirements of this Act to provide coverage for blood testing
22 for perfluoroalkyl and polyfluoroalkyl substances for the purposes of appropriate
23 management or ongoing monitoring of a disease or condition when supported by medical
24 and scientific evidence are not an expansion of the State's essential health benefits and do
25 not require defrayal of costs by the State pursuant to 42 United States Code, Section
26 18031(d)(3)(B) because the State's essential health benefits currently include coverage for
27 outpatient laboratory services.
28
29 executed, delivered, issued for delivery, continued or renewed in this State on or after
30 January 1, 2026. For purposes of this Act, all contracts are deemed to be renewed no later
31 than the next yearly anniversary of the contract date.
32
33 This bill requires carriers offering health plans in this State to provide coverage for
34 blood testing for perfluoroalkyl and polyfluoroalkyl substances, or PFAS, recommended
35 by a provider as medically necessary health care in accordance with clinical guidelines
36 established by the National Academies of Sciences, Engineering, and Medicine. The
37 requirements of the bill apply to health plans issued or renewed on or after January 1, 2026.
38 The bill also includes language stating the Legislature's finding that the requirement for
39 coverage for blood testing for perfluoroalkyl and polyfluoroalkyl substances are not an
40 expansion of the State's essential health benefits and do not require the State to defray costs
41 pursuant to the federal Patient Protection and Affordable Care Act.
33
34
35
36
37
38
39
40
41